Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62).
about
Patient perceptions of quality of life with diabetes-related complications and treatmentsHealth and economic impact of combining metformin with nateglinide to achieve glycemic control: Comparison of the lifetime costs of complications in the U.KEmerging utility of once-weekly exenatide in patients with type 2 diabetesThe system of care for the diabetic foot: objectives, outcomes, and opportunitiesOptimizing chronic disease management mega-analysis: economic evaluationCost-effectiveness of self-monitoring of blood glucose in patients with type 2 diabetes mellitus managed without insulinCost-Effectiveness of Saxagliptin versus Acarbose as Second-Line Therapy in Type 2 Diabetes in ChinaCost effectiveness and value of information analyses of islet cell transplantation in the management of 'unstable' type 1 diabetes mellitusThe effect of diabetes complications on health-related quality of life: the importance of longitudinal data to address patient heterogeneity.Refitting of the UKPDS 68 risk equations to contemporary routine clinical practice data in the UK.The impact of chronic heart failure on health-related quality of life data acquired in the baseline phase of the CARE-HF study.A cost effectiveness study of integrated care in health services delivery: a diabetes program in Australia.The consequences of delaying insulin initiation in UK type 2 diabetes patients failing oral hyperglycaemic agents: a modelling studyA review of methods used in long-term cost-effectiveness models of diabetes mellitus treatment.Diabetic neuropathy: mechanisms to managementImpact of symptoms on quality of life before and after diagnosis of coeliac disease: results from a UK population survey.Costs and benefits of free medications after myocardial infarction.The relationship between staff skill mix, costs and outcomes in intermediate care services.Cost-Effectiveness of Liraglutide Versus Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus in the UK.Health utilities of type 2 diabetes-related complications: a cross-sectional study in Sweden.Ethnic differences in health related quality of life for patients with type 2 diabetesHealth-related quality of life and health preference of Chinese patients with diabetes mellitus managed in primary care and secondary care setting: decrements associated with individual complication and number of complicationsCan Sophie's choice be adequately captured by cold computation of minimizing losses? An fMRI study of vital loss decisions.Patient-reported outcomes in the practice-based opportunities for weight reduction (POWER) trial.Delivering the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cost effectiveness analysis.Health related quality of life in patients with type 2 diabetes mellitus in Iran: a national survey.Health-related quality of life in diabetic people with different vascular risk.Automated bolus advisor control and usability study (ABACUS): does use of an insulin bolus advisor improve glycaemic control in patients failing multiple daily insulin injection (MDI) therapy? [NCT01460446].Weight-related quality of life, health utility, psychological well-being, and satisfaction with exenatide once weekly compared with sitagliptin or pioglitazone after 26 weeks of treatment.A comparison of health-related quality of life (health utility) between insulin degludec and insulin glargine: a meta-analysis of phase 3 trials.Examining the impact of 11 long-standing health conditions on health-related quality of life using the EQ-5D in a general population sample.Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes.Nerve growth factor mediates mechanical allodynia in a mouse model of type 2 diabetes.A 16-week open-label, multicenter pilot study assessing insulin pump therapy in patients with type 2 diabetes suboptimally controlled with multiple daily injections.Economic evaluation of hormonal therapies for postmenopausal women with estrogen receptor-positive early breast cancer in CanadaCost-effectiveness of second-line antihyperglycemic therapy in patients with type 2 diabetes mellitus inadequately controlled on metforminAn estimation of the long-term clinical and economic benefits of insulin lispro in Type 1 diabetes in the UK.Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System PerspectiveCost-effectiveness of intensive multifactorial treatment compared with routine care for individuals with screen-detected Type 2 diabetes: analysis of the ADDITION-UK cluster-randomized controlled trial.Which health-related quality of life score? A comparison of alternative utility measures in patients with Type 2 diabetes in the ADVANCE trial
P2860
Q24644699-E18C2C9B-8105-46C0-B8DE-CD5D81BFE7E9Q24797434-C8C02A04-E1C5-4167-89FC-BA695B5441B8Q26777320-589C6347-AC7D-4AF7-8B87-256B813BD07FQ26861462-D995FA88-0289-41AC-9D2D-4BB2D215590FQ27004061-AEF3BC9B-FBF9-4BA4-BE93-3630E58C23EAQ28268410-3D039D5B-F1E0-4E18-B152-EB5135DEB92FQ28553675-041DEEB9-51AA-426A-BE52-E1D8D660BC9EQ28600953-3504B6F3-9668-418A-A21D-6CE81CB1C97BQ30654773-2FD3F33B-83FB-4CF1-BAA5-76597B37BA03Q30863970-18800426-DC77-41ED-8AB3-B30CC7CE55C5Q30982366-B63B18BA-AE8C-462E-8CC3-D4870579DA82Q33373856-FDC16307-D676-4F46-9207-3B7CA4641FD2Q33508691-6EA984B7-9B9E-430D-A46A-A9C903E9CFAAQ33539961-DE122018-098E-41AB-9171-3B1C26D1EB7FQ33554384-E78DE090-720B-4639-B21A-AD96674CD5CBQ33566298-BF1CFDAB-B7CA-4389-9A2C-A23DB06E6A3AQ33585275-3D85EE74-4AAF-4A33-A49F-4C0D97BDFE1AQ33644996-BC75BB64-A2F5-42DD-BBEC-343FDB545EC4Q33732593-1BA920A7-7374-4130-AB2F-0EEB9B2F0785Q33742403-7EB854CB-A99A-40AB-A35A-413B7BA9E913Q33768222-1A1D1617-8F92-475A-904E-E4D1983BF56DQ33795712-329911C6-4200-47AC-A2C6-9BBF86DDA3F1Q33848985-C7B73907-A633-446C-8924-6DB0BFC0791FQ34065435-AFEB4BAA-DFE0-4CEF-B1A8-409AE7981E01Q34077174-4873FB72-5D70-4840-B0E0-7B8D86D3E3D6Q34406787-1D4B8FAF-4B66-408F-9957-BA05FC794ADAQ34418579-C7D27C69-F8E8-4BAA-8757-D7B0E007A288Q34444545-F501B0E9-78A3-4953-88AC-F445ED24218DQ34507074-72A57D7C-F435-4EE3-82E6-70A76FB632B8Q34981168-824262D4-ABE4-4BE4-B4D3-8A4E2913FEA5Q35119071-194DAC8F-6EA6-41F7-BACD-B694462E345FQ35126645-2539DB8C-805B-42FB-AC58-6E5F783F7468Q35184731-AC6051E7-6880-4769-B674-D3EB3047C992Q35336944-91109E79-F010-4092-BC25-965322A65DFAQ35445037-552030D8-2BD7-4C34-8726-C025EB65F3A9Q35551069-B09DF9C6-A3C5-46CA-B5AD-49764F42E5E3Q35585217-62755AA2-8B04-4A74-BE20-F6DCF24DD98BQ35833876-D0DC7282-B2A0-432A-BB82-84F12A35C359Q35877943-0A968F7D-7D8F-41AB-9222-CFBC19A49D92Q35945237-8EF11D2E-442B-49AD-A07C-7FFDE7D2D219
P2860
Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62).
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Estimating utility values for ...... ts using the EQ-5D (UKPDS 62).
@en
Estimating utility values for health states of type 2 diabetic patients using the EQ-5D
@nl
type
label
Estimating utility values for ...... ts using the EQ-5D (UKPDS 62).
@en
Estimating utility values for health states of type 2 diabetic patients using the EQ-5D
@nl
prefLabel
Estimating utility values for ...... ts using the EQ-5D (UKPDS 62).
@en
Estimating utility values for health states of type 2 diabetic patients using the EQ-5D
@nl
P1476
Estimating utility values for ...... ts using the EQ-5D (UKPDS 62).
@en
P2093
Alastair Gray
Rury Holman
P304
P356
10.1177/027298902400448902
P577
2002-07-01T00:00:00Z